Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well golimumab and apalutamide work in treating patients with
castration resistant prostate cancer. Golimumab is in a class of medications called tumor
necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the
body that causes inflammation. Apalutamide is in a class of medications called androgen
receptor inhibitors. It works by blocking the effects of androgen (a male reproductive
hormone) to stop the growth and spread of cancer cells. Giving golimumab and apalutamide may
work better in treating patients with castration-resistant prostate cancer.